Terran Biosciences

Watch this incredible lineup during the Neuroscience Spotlight Sessions at #CNSSummit2024 Harry Tracy | Atul Mahableshwarkar | Johannes Streffer | Kevin Craig | Ryan Field | Thomas Thompson | Gayle Wittenberg, Ph.D. | Corey Reuteman-Fowler, Ph.D. | Anzar Abbas | Spyros Papapetropoulos MD, PhD | Alessio Travaglia | Steve Gardner | Sam Clark, MD PhD | Shane Hegarty | David Pattison, CPA | Wen Luo

🌟 Congratulations to the Fierce Life Sciences Innovation Awards Finalists! 🌟 These remarkable innovators are leading the charge in biotech, drug development, digital health, and more. Their groundbreaking work is setting new standards in the industry, and we can't reveal the winners on December 2nd. Check out the full list of trailblazing finalists here: https://shorturl.at/yBecz Join our mailing list to stay updated on the winners: https://shorturl.at/E1PAg #LifeSciences #Innovation #Biotech #Healthcare #DigitalHealth #Pharma #FierceInnovationAwards #FierceLifeSciences #FierceLifeSciencesInnovationAwards

💊 ⏩ 🧑 The 505(b)(2) pathway enables drugs to more quickly pass through the clinical stage and reach patients. The decision to do so often involves piggybacking on approved meds for a quicker entrance to market. In this Q&A, Sam Clark, MD PhD explains how Terran Biosciences is tagging on to the recent FDA approval of Bristol Meyer Squibb’s Cobenfy (formerly Karuna Therapeutics' KarXT). #clinicaltrials #clinicalresearch

🎥 New Special Report! 🎥 We’re excited to present a special 5-part series on Embracing New Therapies in Schizophrenia Management, with insights from leading subject matter experts Rishi Kakar, MD, of Segal Trials, Andrew Cutler, MD, Neuroscience Education Institute, and moderator Sam Clark, MD PhD, of Terran Biosciences. In this series, we dive deep into the groundbreaking FDA-approved schizophrenia treatment, xanomeline and trospium chloride capsules (Cobenfiy; Bristol Myers Squibb), and its novel mechanism of action targeting muscarinic receptors instead of traditional dopamine pathways. The series highlights key clinical trial data, symptom management, and how these new therapies could revolutionize treatment for patients who haven't fully responded to traditional antipsychotics. Watch and learn how these advancements may shape the future of schizophrenia care, improve patient outcomes, and address unmet needs in managing this complex condition. In the segment below, the experts discuss the application of clinical trial data to real-world settings. Use the link for the full series! https://lnkd.in/eDvyx_9S #Schizophrenia #Neuropsychiatry #MentalHealth #Psychiatry

The latest advancements driving neuroscience drug discovery research In this webinar, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, MD PhD, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX.   Dr Klein shares how Dewpoint applies insights into the subcellular organisation of biochemical processes into membrane-less compartments to discover novel drug targets and revolutionary drugs for diseases with high unmet need, including amyotrophic lateral sclerosis (ALS) and Rett Syndrome. Dr Clark’s presentation will cover the intersection of medicinal chemistry and drug discovery as well as how this can help address the unmet medical need for new therapeutics in the neuropsych space. Professor Roberts will explore how an integrated in vitro seizure liability assay can benefit drug discovery for companies exploring central nervous system diseases. What you will learn: • Where are the breakthroughs in neuroscience research? • How are advanced technologies proving beneficial to drug discovery and development? • How is the current unmet need within drug discovery and development for central nervous system (CNS) disorders providing opportunity? A Q&A session follows the webinar presentations. Mon, Sep 30, 2024 3:00 PM - 4:00 PM BST Register today! https://lnkd.in/em3QDi5n #Neuroscience #Drugdiscovery #DrugDevelopment

🚨 BREAKING NEWS 🚨 The US FDA has announced the approval xanomeline and trospium chloride capsules (Cobenfy), for schizophrenia. The approval, which was awarded to Bristol Myers Squibb, makes Cobenfy the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors https://lnkd.in/gvgU-qee #Schizophrenia #Psychiatry